Stay updated on ARV-471 plus Everolimus in ER+, HER2- Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the ARV-471 plus Everolimus in ER+, HER2- Breast Cancer Clinical Trial page.

Latest updates to the ARV-471 plus Everolimus in ER+, HER2- Breast Cancer Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedCore content updated to include a government-funding operating status advisory and a new revision/version (v3.2.0); previous update label and old revision (v3.1.0) were removed.SummaryDifference4%
- Check20 days agoChange DetectedThe page has been updated with newer revision details (v3.1.0), dates, and policy notes (IPD plan), while older statuses and legacy dates (e.g., Active, not recruiting; 2024 dates) were removed. This signals an update to product information and governance without altering core content.SummaryDifference3%
- Check27 days agoNo Change Detected
- Check34 days agoChange DetectedUpdated page revision from v3.0.1 to v3.0.2 and removed the 'Back to Top' element. No other substantive content changes (pricing, stock, or time slot availability) are indicated.SummaryDifference0.3%
- Check41 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes to core content or other important elements.SummaryDifference0.3%
- Check49 days agoChange DetectedThe web page has updated its facility name and location details, specifically adding 'Washington D.C., District of Columbia, United States, 20007' and 'Skin and Connective Tissue Diseases', while removing several related medical topics and previous location terms.SummaryDifference3%
- Check63 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.1%
Stay in the know with updates to ARV-471 plus Everolimus in ER+, HER2- Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ARV-471 plus Everolimus in ER+, HER2- Breast Cancer Clinical Trial page.